UnipharDUB:UPR +2.69%84 Buyback Yield % is 2.96 as of Jul. 04, 2026. GuruFocus rates DUB:UPR with a GF Score™ of 84/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 40 Medical Distribution companies, Uniphar ranks better than 75% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Uniphar's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DUB:UPR vs MCK, CAH, COR: Buyback Yield % Comparison
For the Medical Distribution subindustry, Uniphar's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Uniphar's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar (DUB:UPR) has a Buyback Yield % of 2.96 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Uniphar and its competitors. According to the industry distribution chart, Uniphar ranks #10 out of 40 companies in the Medical Distribution industry, placing it in the top 25%.
Is Uniphar's Buyback Yield % too high?
Uniphar's current Buyback Yield % is 2.96. The Medical Distribution industry median Buyback Yield % is 0.02. Uniphar's value of 2.96 is 14700% above this industry median. Based on the distribution chart, Uniphar ranks #10 out of 40 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Uniphar has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Buyback Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Uniphar ranks #10 out of 40 companies for Buyback Yield %. This places Uniphar in the top 25% of its industry — outperforming the majority of peers. The industry median Buyback Yield % is 0.02. Uniphar's value of 2.96 is 14700% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.02, based on 40 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current Buyback Yield % of 2.96 is 14700% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current Buyback Yield % is 2.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.78 — trading 31.3% above its estimated fair value. The current Buyback Yield % is 2.96 and 14700% above the Medical Distribution industry median of 0.02. Uniphar's overall GF Score™ is 84/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Buyback Yield % is 2.96 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.78 is trading 31.3% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Significantly Overvalued.
Key valuation signals for DUB:UPR:
Buyback Yield %: 2.96
GF Value™: €3.64 vs. price of €4.78 (31.3% above fair value)
Industry Position: 14700% above the Medical Distribution median (#10 of 40)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
84GF Score
Get the complete analysis for DUB:UPR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
